Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 13/20 | 0.58 |
| ▸ | KDR | P35968 | 9/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | UBE2N | P61088 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30303944 | 1.00 | TEK (0.58) | TEKKDRGSK3BKDM4EALDH1A1 | |
| SCHEMBL22676043 | 0.83 | CYP3A4 (0.44) | TEKKDR | |
| SCHEMBL22675812 | 0.82 | KDR (0.50) | TEKKDR | |
| SCHEMBL30303910 | 0.82 | KDR (0.50) | TEKKDR | |
| SCHEMBL22675924 | 0.81 | FGFR1 (0.65) | TEKKDRAURKAAURKB | |
| SCHEMBL30303590 | 0.81 | FGFR1 (0.65) | TEKKDRAURKAAURKB | |
| SCHEMBL25129345 | 0.80 | TEK (0.52) | TEKKDRGSK3BKDM4EALDH1A1 | |
| SCHEMBL22676520 | 0.79 | CYP3A4 (0.53) | TEKKDR | |
| SCHEMBL22676841 | 0.79 | KDR (0.50) | TEKKDRGSK3BFLT1AURKA | |
| SCHEMBL22658711 | 0.79 | FGFR1 (0.42) | TEKKDRGSK3BFLT1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | TEK 184/4885KDR 80/4885GSK3B 126/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | TEK 184/4885KDR 80/4885GSK3B 126/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | TEK 184/4885KDR 80/4885GSK3B 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.